Chenyu Lin, MD
@ChenyuLinMD
Followers
578
Following
2K
Media
72
Statuses
534
Oncologist & Clinical Investigator @DukeCancer | Med Director, Cellular Therapy Program | Leukemia/Lymphoma, Digital Health | Posts ≠ med advice
Durham, NC
Joined May 2021
Congrats to @CanerSaygin and several leukemia program faculty including @Anand_88_Patel @DrWendyStock @myeloidmalig @AyaOncologist @michaelwd_hem on this effort characterizing outcomes in TP53m ALL https://t.co/WMKdKYdMkO
2
11
48
I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇 https://t.co/3oDrO4k96j 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS
1
22
58
Early View | Haematologica https://t.co/F3vHTQBjOp Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) led
1
7
35
LLS is rebranding as Blood Cancer United on Aug 28 to reflect support for all 100+ blood cancers. 🩸 Broader reach, unified purpose 🩸 New name, same mission @LLSusa
https://t.co/39C1eQp9aa
#HemOnc #BloodCancer
0
3
6
New article alert! 🚨🚨 Dr. @Anand_88_Patel and 3rd year @UCHemOncFellows Dr. Yates are published in @Haematologica sharing the results of the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)! https://t.co/zu9vzEpli6
0
3
11
Established Investigators need to rank in the 4th percentile, whereas Early Investigators need to be in the 10th percentile. This means that among 80 reviews in a study section, only 3 will be below the 4th percentile.
cancer.gov
NCI funding policy for research project grant (RPG) awards reflects the funding goals of the institute, NIH, and HHS.
1
6
8
In the latest ASTCT Talks episode, Dr. Shernan Holtan sits down with renowned leader, mentor & pioneer in cell therapy & transplantation, Dr. Daniel Weisdorf. Listen now on the ASTCT website or wherever you access podcasts: https://t.co/4uA1EqRmfC
0
1
3
Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm
https://t.co/eOFcea9ahg
1
3
10
Don’t let the name fool you—we are here for all blood cancers, from A to Z (AML to Waldenström’s)
1
6
31
@US_FDA approves bispecific antibody, Lynozyfic (linvoseltamab), for treatment of relapsed/refractory #myeloma patients who have received 4 prior lines of therapy. https://t.co/z4uezcmJ8X Learn more about LINKER-MM1 study.
investor.regeneron.com
TARRYTOWN, N.Y. , July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
0
2
4
Great work from @RahulBanerjeeMD and others leveraging real world data to demonstrate the feasibility of relaxing these requirements!
0
1
6
🚨The requirement to stay within proximity of CART center for #Breyanzi and #Abecma reduced from 4 to 2 weeks! Driving restrictions down from 8 to 2 weeks! Major change for patients and institutions, making #CART more accessible to all. https://t.co/cmQ5clRJyR
targetedonc.com
FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.
1
1
22
🎙️ Just out on @ASTCT’s #TitansOfTransplant: I sit down with my mentor and transplant trailblazer, Dr. @DanielWeisdorf. We trace the field's evolution and future frontiers, from sibling-only marrow harvests to cord-blood breakthroughs and next-gen GVHD prevention. Dan’s wisdom
0
7
25
This @CIBMTR registry study published in @Bloodneoplasia showed similar survival and faster neutrophil engraftment with #omidubicel transplantation vs. alternative stem cell sources, led by @DukeCancer faculty @ChenyuLinMD @horwi001. #BMTsm #CordBlood
https://t.co/2QKLKgYEyh
0
2
9
The #MZL cohort of the TRANSCEND FL trial demonstrated high rates of durable responses with liso-cel in patients with relapsed/ refractory #MZL.@icmlugano #18ICML
https://t.co/qVs6u9XouE
targetedonc.com
Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.
1
1
3
ASTCT & @CancerNetwrk organized an X Space hosted by Rahul Banerjee; Taha Al-Juhaishi & Muhammad Salman Faisal to discuss key presentations and abstracts of interest at the 2025 ASCO Annual Meeting. Listen now to catch up on what was discussed: https://t.co/eJc3L4wrUE
0
3
4
An investigator-initiated clinical trial evaluating #Ruxolitinib and #Fostamatinib for steroid-refractory chronic #GVHD is now accruing at @DukeCancer, one of few combinatorial regimens being tested, based on work from #SarantopoulosLab. PIs @ChenyuLinMD @horwi001 #BMTsm
0
3
8
Are you thinking about manufacturing your own #CARtcell or developing a program for that at your own institution? Check out our @ASTCT Talks podcast on this topic with the world expert on this, Dr @DrMarcosdelima #bmtsm #CellTherapy
https://t.co/gr2mRI6QA1
astct.org
In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Marcos de Lima, hematologist-oncologist at The Ohio State University Comprehensive Cancer Center, to explore the rapidly evolving...
1
4
14
The birth of cancer immunotherapies field in oncology followed this #bmtsm data from the 1970s, landmark discovery of GVHD following AlloHSCT is associated with less cancer relapse #ASCO25 Weiden et al, NEJM 1979, also check out nice summary below https://t.co/aCm7wwu6G9
0
11
34
#ASCO25 #Ph_pos_ALL phase 1 study presented by Dr @LuskinMarlise Asciminib+Dasatinib+Prednisone followed by blinatumomab is safe and effective in achieving deep molecular remission. #leusm
4
22
76